43.84 USD
-0.52 (-1.17%)
43.84 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to VCYT. VCYT was compared to 531 industry peers in the Biotechnology industry. VCYT has an excellent financial health rating, but there are some minor concerns on its profitability. VCYT is not overvalued while it is showing excellent growth. This is an interesting combination. This makes VCYT very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year VCYT was profitable.
In the past year VCYT had a positive cash flow from operations.
In the past 5 years VCYT reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: VCYT reported negative operating cash flow in multiple years.
1.2 Ratios
VCYT has a better Return On Assets (2.22%) than 89.08% of its industry peers.
Looking at the Return On Equity, with a value of 2.41%, VCYT belongs to the top of the industry, outperforming 90.21% of the companies in the same industry.
VCYT has a Return On Invested Capital of 2.93%. This is amongst the best in the industry. VCYT outperforms 89.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROIC | 2.93% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT's Profit Margin of 6.12% is amongst the best of the industry. VCYT outperforms 90.02% of its industry peers.
VCYT's Operating Margin of 9.70% is amongst the best of the industry. VCYT outperforms 91.53% of its industry peers.
With an excellent Gross Margin value of 68.53%, VCYT belongs to the best of the industry, outperforming 80.98% of the companies in the same industry.
In the last couple of years the Gross Margin of VCYT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
VCYT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
VCYT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VCYT has more shares outstanding
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 19.26 indicates that VCYT is not in any danger for bankruptcy at the moment.
VCYT has a Altman-Z score of 19.26. This is amongst the best in the industry. VCYT outperforms 88.14% of its industry peers.
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.26 |
ROIC/WACC0.33
WACC8.81%
2.3 Liquidity
A Current Ratio of 6.23 indicates that VCYT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.23, VCYT is in the better half of the industry, outperforming 64.22% of the companies in the same industry.
A Quick Ratio of 5.94 indicates that VCYT has no problem at all paying its short term obligations.
VCYT has a better Quick ratio (5.94) than 63.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
VCYT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 353.33%, which is quite impressive.
VCYT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.41%.
Measured over the past years, VCYT shows a very strong growth in Revenue. The Revenue has been growing by 29.93% on average per year.
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
3.2 Future
The Earnings Per Share is expected to grow by 52.24% on average over the next years. This is a very strong growth
Based on estimates for the next years, VCYT will show a quite strong growth in Revenue. The Revenue will grow by 11.54% on average per year.
EPS Next Y74.53%
EPS Next 2Y86.75%
EPS Next 3Y59.6%
EPS Next 5Y52.24%
Revenue Next Year14.36%
Revenue Next 2Y12.54%
Revenue Next 3Y12.19%
Revenue Next 5Y11.54%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 115.37, which means the current valuation is very expensive for VCYT.
VCYT's Price/Earnings ratio is rather cheap when compared to the industry. VCYT is cheaper than 89.45% of the companies in the same industry.
When comparing the Price/Earnings ratio of VCYT to the average of the S&P500 Index (26.28), we can say VCYT is valued expensively.
Based on the Price/Forward Earnings ratio of 41.90, the valuation of VCYT can be described as expensive.
Based on the Price/Forward Earnings ratio, VCYT is valued cheaply inside the industry as 91.34% of the companies are valued more expensively.
VCYT is valuated expensively when we compare the Price/Forward Earnings ratio to 23.52, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 115.37 | ||
| Fwd PE | 41.9 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VCYT is valued cheaper than 91.15% of the companies in the same industry.
VCYT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VCYT is cheaper than 93.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.29 | ||
| EV/EBITDA | 43.31 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of VCYT may justify a higher PE ratio.
VCYT's earnings are expected to grow with 59.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.55
PEG (5Y)N/A
EPS Next 2Y86.75%
EPS Next 3Y59.6%
5. Dividend
5.1 Amount
VCYT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
43.84
-0.52 (-1.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners114.7%
Inst Owner Change3.31%
Ins Owners0.46%
Ins Owner Change-2.17%
Market Cap3.47B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts82.11
Price Target49.33 (12.52%)
Short Float %6.93%
Short Ratio5.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)14.88%
PT rev (3m)17.32%
EPS NQ rev (1m)8.52%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)31.06%
EPS NY rev (3m)39.68%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)1.31%
Revenue NY rev (3m)1.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 115.37 | ||
| Fwd PE | 41.9 | ||
| P/S | 7 | ||
| P/FCF | 35.29 | ||
| P/OCF | 32.01 | ||
| P/B | 2.76 | ||
| P/tB | 8.71 | ||
| EV/EBITDA | 43.31 |
EPS(TTM)0.38
EY0.87%
EPS(NY)1.05
Fwd EY2.39%
FCF(TTM)1.24
FCFY2.83%
OCF(TTM)1.37
OCFY3.12%
SpS6.26
BVpS15.91
TBVpS5.04
PEG (NY)1.55
PEG (5Y)N/A
Graham Number11.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROCE | 3.71% | ||
| ROIC | 2.93% | ||
| ROICexc | 4.08% | ||
| ROICexgc | 54.52% | ||
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% | ||
| FCFM | 19.83% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 44.87% | ||
| Cap/Sales | 2.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.79% | ||
| Profit Quality | 323.94% | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z | 19.26 |
F-Score8
WACC8.81%
ROIC/WACC0.33
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y74.53%
EPS Next 2Y86.75%
EPS Next 3Y59.6%
EPS Next 5Y52.24%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year14.36%
Revenue Next 2Y12.54%
Revenue Next 3Y12.19%
Revenue Next 5Y11.54%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year319.96%
EBIT Next 3Y74.15%
EBIT Next 5Y47.08%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A
VERACYTE INC / VCYT FAQ
What is the fundamental rating for VCYT stock?
ChartMill assigns a fundamental rating of 6 / 10 to VCYT.
What is the valuation status for VCYT stock?
ChartMill assigns a valuation rating of 6 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.
How profitable is VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a profitability rating of 6 / 10.
How financially healthy is VERACYTE INC?
The financial health rating of VERACYTE INC (VCYT) is 8 / 10.
What is the expected EPS growth for VERACYTE INC (VCYT) stock?
The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 74.53% in the next year.